ClinicalTrials.gg
CompletedNCT05978713Updated Apr 27, 2025Results posted

A Study of Tirzepatide (LY3298176) in Healthy Lactating Females

A Phase 1 interventional study of Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The main purpose of this study was to look if the study drug, tirzepatide, gets into the breastmilk and, if yes, how long it takes the body to get rid of it from the breastmilk. The study drug was given as a single injection under the skin in healthy lactating females. For each participant, the total duration of the study was approximately 8 weeks, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy females as determined by medical evaluation
  • Female participants who delivered normal-term infant (at least 37 weeks gestation) and are at least 6 weeks postpartum at the time of screening
  • (BMI) between 18.5 and 40.0 kilograms per meter squared (kg/m²), inclusive
  • Female participants who has well-established lactation and is breastfeeding her infant. Note: Breastfeeding must be discontinued prior to the administration of tirzepatide on Day 1 and not resumed for the remaining duration of the study until a follow-up visit (or for total of 29 days after tirzepatide dosing for participants who discontinue early).

Exclusion criteria

Exclusion Criteria:

  • Have a history of inadequate lactation (for multiparous females who have previously breastfed)
  • Have confirmed type 1 or type 2 diabetes mellitus
  • Regularly use known drugs of abuse or show positive findings on drug screen
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    5 mg Tirzepatide

    Participants received a single dose of 5 mg tirzepatide injection administered subcutaneously (SC).

    Drug: Tirzepatide

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞])

    PK: AUC (0-∞) of Tirzepatide excreted in Breastmilk

    Time frame: Predose, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 168, 336, 504, 672 hours post-dose

07

Results

Posted Apr 27, 2025

Participant flow

Participant flow — Overall Study
Milestone5 mg Tirzepatide
Started11
Received a dose of tirzepatide11
Completed11
Not completed0

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞])

PK: AUC (0-∞) of Tirzepatide excreted in Breastmilk

Time frame:
Predose, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 168, 336, 504, 672 hours post-dose
Reported as:
Geometric mean · nanogram*hours per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞])
nanogram*hours per milliliter (ng*h/mL)5 mg Tirzepatide
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞])NA ± NA

Adverse events

Collected over Baseline to the end of follow-up (up to Day 29). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide0/11 (0%)0/11 (0%)11/11 (100%)
Most frequent other events
Showing 10 of 20
Most frequent other events
Event5 mg Tirzepatide
Decreased appetiteMetabolism and nutrition disorders10/11
NauseaGastrointestinal disorders9/11
DiarrhoeaGastrointestinal disorders7/11
HeadacheNervous system disorders5/11
VomitingGastrointestinal disorders4/11
FatigueGeneral disorders4/11
Abdominal distensionGastrointestinal disorders3/11
Abdominal discomfortGastrointestinal disorders2/11
MyalgiaMusculoskeletal and connective tissue disorders2/11
Abdominal painGastrointestinal disorders1/11

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide
Mean32.7 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide
Female11
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide
Hispanic or Latino3
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American2
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)5 mg Tirzepatide
United States11
08

Study locations

1 site
  • Las Vegas Clinical Research Unit - PPD
    Las Vegas, Nevada 89113-2228, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Mar 2024, 7 months.

Results were first posted in Apr 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Aug 7, 2023
StartActual
Jul 31, 2023
Primary completionActual
Mar 12, 2024
CompletionActual
Mar 12, 2024
Results first posted
Apr 27, 2025
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05978713
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Jul 31, 2023
Primary completion
Mar 12, 2024
Completion
Mar 12, 2024
Results posted
Apr 27, 2025
Last update
Apr 27, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion